# nature portfolio

Corresponding author(s): JUAN ANGUITA/LETICIA ABECIA

Last updated by author(s): Jul 11, 2023

# **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

#### Statistics

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	firmed
	$\boxtimes$	The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
		A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	$\boxtimes$	A description of all covariates tested
	$\boxtimes$	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
		A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
		For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.
$\ge$		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
$\boxtimes$		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	$\boxtimes$	Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

### Software and code

Policy information about <u>availability of computer code</u>					
Data collection	no software was used				
Data analysis	Frida software, flowJo, QIIME1.9, DESeq2, LEfSe, R packages, HAIIA (Hierarchical All-against-All significance testing), GraphPad software				

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

#### Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Raw sequences used for metagenomics analysis were uploaded to European Nucleotide Archive (ENA www.ebi.ac.uk/ena) under the project number PRJEB43545 for IgA experiment, PRJEB43544 for Germ-Free mice experiment and PRJEB43553 for cohousing.

### Research involving human participants, their data, or biological material

Policy information about studies with <u>human participants or human data</u>. See also policy information about <u>sex, gender (identity/presentation),</u> <u>and sexual orientation</u> and <u>race, ethnicity and racism</u>.

Reporting on sex and gender	Use the terms sex (biological attribute) and gender (shaped by social and cultural circumstances) carefully in order to avoid confusing both terms. Indicate if findings apply to only one sex or gender; describe whether sex and gender were considered in study design; whether sex and/or gender was determined based on self-reporting or assigned and methods used. Provide in the source data disaggregated sex and gender data, where this information has been collected, and if consent has been obtained for sharing of individual-level data; provide overall numbers in this Reporting Summary. Please state if this information has not been collected. Report sex- and gender-based analyses where performed, justify reasons for lack of sex- and gender-based analysis.
Reporting on race, ethnicity, or other socially relevant groupings	Please specify the socially constructed or socially relevant categorization variable(s) used in your manuscript and explain why they were used. Please note that such variables should not be used as proxies for other socially constructed/relevant variables (for example, race or ethnicity should not be used as a proxy for socioeconomic status). Provide clear definitions of the relevant terms used, how they were provided (by the participants/respondents, the researchers, or third parties), and the method(s) used to classify people into the different categories (e.g. self-report, census or administrative data, social media data, etc.) Please provide details about how you controlled for confounding variables in your analyses.
Population characteristics	Describe the covariate-relevant population characteristics of the human research participants (e.g. age, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."
Recruitment	Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.
	Identify the organization(s) that approved the study protocol.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

### Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences 🗌 Behavioural & social sciences 🗌 Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

# Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Sample size was stimated by Gpower
Data exclusions	No data were excluded
Replication	We used a number of mice to show that the results can be replicated
Randomization	Allocation was random
Blinding	Blinding was not possible, but measurement were objectives.

### Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Ma	terials & experimental systems	Methods	
n/a	Involved in the study	n/a	Involved in the study
	X Antibodies	$\boxtimes$	ChIP-seq
$\boxtimes$	Eukaryotic cell lines		Flow cytometry
$\boxtimes$	Palaeontology and archaeology	$\boxtimes$	MRI-based neuroimaging
	Animals and other organisms		
$\boxtimes$	Clinical data		
$\times$	Dual use research of concern		
	Plants		

### Antibodies

	CD11b APC (Miltenyi Biotech, M1/70); CD11c PE Cy7 (Miltenyi Biotech, N418); CD103 PE (Miltenyi Biotech, REA789); F4/80 FITC (Miltenyi biotech, REA126); Fc receptors were blocked with Anti-mCD16/CD32 (BD)
Validation	Experience from our laboratory

### Animals and other research organisms

Policy information about studies involving animals; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in</u> <u>Research</u>

MCJ-deficient and Wild-Type (WT) mice on a C57BL/6 background were used (4-10 week old)
Study did not involved wild animals
Findings apply to both sexs.
Standard housing conditions (21–23°C temperature and 12/12-hour light/dark cycles)
Animal Research Ethics Board of the CIC bioGUNE (Spain; permit number CBBA-0615).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

### Flow Cytometry

#### Plots

Confirm that:

 $\square$  The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

 $\bigotimes$  All plots are contour plots with outliers or pseudocolor plots.

X A numerical value for number of cells or percentage (with statistics) is provided.

#### Methodology

Sample preparation	Mesenteric lymph nodes cells
Instrument	FACSCanto II flow cytometer
Software	flowJo v10
Cell population abundance	10-20%
Gating strategy	Lymphocytes (FSC-A vs SSC-A), sincle cells (SSC-W vs SSC-A), CD 103 PE FSC-A

X Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.